Access requires that you are 21 years of age or older. Products are for laboratory and research use only — not for human or veterinary use, consumption, or clinical application.
KLOW reference material, supplied as a lyophilized powder in a sealed vial for in-vitro laboratory research and analytical method development. Each fill size is a separate SKU. Lot and COA records are shown when assigned.
This listing is a research chemical / reference material. No therapeutic, preventive, or diagnostic claims are made or implied. The storefront displays only approved analytical characterization data released through its public report records.
KLOW is a blend of 4 separately studied peptides, not a single molecule. Each has its own monograph here, carrying that component's identity, history and evidence:
KLOW is a four-component blend: kpv, ghk-cu, bpc-157 and tb-500. Not a single molecule. A four-way co-formulation. Each component has its own monograph here carrying its identity, history and evidence.
Each component has its own reported mechanism. There is no combined-mechanism study of the four together in our sources. Vectra makes no claim as to mechanism or effect.
No development history. A vendor and community formulation rather than a developed product.
The four components have individual research contexts. The combination has none. Vectra supplies it as a reference material for in-vitro laboratory research and analytical method development only.
No human trial, PMID or peer-reviewed study of this four-component blend exists. Every claim traces back to a component studied alone. Combining four substances multiplies the unknowns rather than averaging them.
No systematic safety, interaction or stability data exists for the combination. A safety profile would have to account for all four components separately, and for any interaction between them, which is unstudied.
Not approved. Two components carry their own restrictions. KPV has been on the FDA 503A Category 2 list since 2023. GHK-Cu is scheduled for advisory review before the end of February 2027. No therapeutic, preventive, or diagnostic claims are made or implied.
Yes — in more than one way:
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.